Neurogenic overactive bladder in spinal cord injury and multiple sclerosis: role of onabotulinumtoxinA

References

• Khan F, Pallant JF, Shea TL, Whishaw M. Multiple sclerosis: prevalence and factors impacting bladder and bowel function in an Australian community cohort. Disabil Rehabil. 2009;31:1567–1576.19848557
   PubMed Web of Science ®Google Scholar
• Anderson KD. Targeting recovery: priorities of the spinal cord-injured population. J Neurotrauma. 2004;21:1371–1383.15672628
   PubMed Web of Science ®Google Scholar
• Bloemen-Vrencken JH, Post MW, Hendriks JM, De Reus EC, De Witte LP. Health problems of persons with spinal cord injury living in The Netherlands. Disabil Rehabil. 2005;27:1381–1389.16321920
   PubMed Web of Science ®Google Scholar
• Simpson LA, Eng JJ, Hsieh JT, Wolfe DL. SCIRE Research Team. The health and life priorities of individuals with spinal cord injury: a systematic review. J Neurotrauma. 2012;29:1548–1555.22320160
   PubMed Web of Science ®Google Scholar
• Abrams P, Cardozo L, Fall M, et al. Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167–178.11857671
   PubMed Web of Science ®Google Scholar
• Thor K, Kawatani M, de Groat WC. Plasticity in the reflex pathways to the lower urinary tract of the cat during postnatal development and following spinal cord injury In: Goldberger ME, Gorio A, Murray M, editors. Development and Plasticity of the Mammalian Spinal Cord. Padova, Italy: Liviana Press; 1986.
   Google Scholar
• de Groat WC. Central neural control of the lower urinary tract In: Bock G, Whelan J, editors. Neurobiology of Incontinence. Chichester, UK: John Wiley; 1990.
   Google Scholar
• Wiart L, Joseph PA, Petit H, et al. The effects of capsaicin on the neurogenic hyperreflexic detrusor. A double blind placebo controlled study in patients with spinal cord disease. Preliminary results. Spinal Cord. 1998;36:95–99.9494998
   PubMed Web of Science ®Google Scholar
• Fowler CJ, Beck RO, Gerrard S, Betts CD, Fowler CG. Intravesical capsaicin for treatment of detrusor hyperreflexia. J Neurol Neurosurg Psychiatry. 1994;57:169–173.8126498
   PubMed Web of Science ®Google Scholar
• Brady CM, Apostolidis A, Yiangou Y, et al. P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin. Eur Urol. 2004;46:247–253.15245821
   PubMed Web of Science ®Google Scholar
• Smet P, Moore K, Jonavicius J. Distribution and colocalization of calcitonin gene-related peptide, tachykinins and vasoactive intestinal polypeptide in normal and idiopathic unstable human urinary bladder. Lab Invest. 1997;77:37–49.9251677
   PubMed Web of Science ®Google Scholar
• McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol. 2002;167(2 Pt 2):1049–1053.11905876
   PubMed Web of Science ®Google Scholar
• Lapides J, Diokno AC, Silber SM, Lowe BS. Clean, intermittent self-catheterization in the treatment of urinary tract disease. J Urol. 2002;167:1584–1586.11912368
   PubMed Web of Science ®Google Scholar
• Kessler TM, Bachmann LM, Minder C, et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One. 2011;6:e16718.21373193
   PubMed Web of Science ®Google Scholar
• Herschorn S, Stothers L, Carlson K, et al. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. J Urol. 2010;183:1892–1898.20303119
   PubMed Web of Science ®Google Scholar
• Pagoria D, O’Connor RC, Guralnick ML. Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients. Curr Urol Rep. 2011;12:351–357.21607875
   PubMedGoogle Scholar
• Wagg A, Dale M, Tretter R, Stow B, Compion G. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol. 2013;64: 74–81.23332882
   PubMed Web of Science ®Google Scholar
• Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63:296–305.23195283
   PubMed Web of Science ®Google Scholar
• Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139:919–922.3361663
   PubMed Web of Science ®Google Scholar
• Mehta S, Hill D, Foley N, et al. Meta-analysis of botulinum toxin sphincteric injections in the treatment of incomplete voiding after spinal cord injury. Arch Phys Med Rehabil. 2012;93:597–603.22365478
   PubMed Web of Science ®Google Scholar
• Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164:692–697.10953127
   PubMed Web of Science ®Google Scholar
• Reitz A, Stöhrer M, Kramer G, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol. 2004;45:510–515.15041117
   PubMed Web of Science ®Google Scholar
• Schurch B, de Sèze M, Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174:196–200.15947626
   PubMed Web of Science ®Google Scholar
• Herschorn S, Gajewski J, Ethans K, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185:2229–2235.21497851
   PubMed Web of Science ®Google Scholar
• Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60:742–750.21798658
   PubMed Web of Science ®Google Scholar
• Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187:2131–2139.22503020
   PubMed Web of Science ®Google Scholar
• Rovner E, Dmochowski R, Chapple C, Thompson C, Lam W, Haag-Molkenteller C. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32:1109–1115.23389824
   PubMed Web of Science ®Google Scholar
• Wagner TH, Patrick DL, Bavendam TG, Martin ML, Buesching DP. Quality of life of persons with urinary incontinence: development of a new measure. Urology. 1996;47:67–71.8560665
   PubMed Web of Science ®Google Scholar
• Ghei M, Maraj BH, Miller R, et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol. 2005;174:1873–1877.16217327
   PubMed Web of Science ®Google Scholar
• Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibres following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005;174:977–982.16094018
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Zabbarova IV, Birder LA, et al. Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder. Eur Urol. 2012;62:1157–1164.22480459
   PubMed Web of Science ®Google Scholar
• Mehnert U, Birzele J, Reuter K, Schurch B. The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study. J Urol. 2010;184:1011–1016.20643431
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Safety and efficacy study onabotulinumtoxinA for the treatment of urinary incontinence in multiple sclerosis. Identifier NCT01600716. Available from: http://clinicaltrials.gov/show/NCT01600716 Accessed January 17, 2014.
   Google Scholar
• Abdel-Meguid TA. Botulinum toxin-A injections into neurogenic overactive bladder-to include or exclude the trigone? A prospective, randomized, controlled trial. J Urol. 2010;184:2423–2428.20952003
   PubMed Web of Science ®Google Scholar
• Mascarenhas F, Cocuzza M, Gomes CM, Leão N. Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients. Neurourol Urodyn. 2008;27:311–314.17914742
   PubMed Web of Science ®Google Scholar
• Krhut J, Samal V, Nemec D, Zvara P. Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study. Spinal Cord. 2012;50:904–907.22801191
   PubMed Web of Science ®Google Scholar
• Kuo HC. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology. 2006;68:993–997.17113890
   PubMed Web of Science ®Google Scholar
• Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology. 2006;68:1193–1197.17141831
   PubMed Web of Science ®Google Scholar
• Giannantoni A, Mearini E, Del Zingaro M, Porena M. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol. 2009;55:705–711.18814955
   PubMed Web of Science ®Google Scholar
• Kennelly M, Dmochowski R, Ethans K, et al. Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis. Urology. 2013;81:491–497.23290144
   PubMed Web of Science ®Google Scholar
• Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron RL. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol. 2007;52:850–858.17467889
   PubMed Web of Science ®Google Scholar
• Sussman D, Patel V, Del Popolo G, Lam W, Globe D, Pommerville P. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32: 242–249.22965657
   PubMed Web of Science ®Google Scholar
• Chancellor MB, Patel V, Leng WW, et al. OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity. Neurology. 2013;81:841–848.23892704
   PubMed Web of Science ®Google Scholar